Proliferative diabetic retinopathy in severe stages: modern approaches to diagnosis and treatment (systematic review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Diabetic retinopathy (DR) is a leading complication in patients with diabetes mellitus (DM). Because of the increase in the clinical effectiveness of treatment for diabetes, the life expectancy of patients has increased, which accordingly increases the risk of severe forms of DR (proliferative DR), which is one of the main causes of blindness and low vision in the working-age population. In the literature, the overall prevalence of DR and proliferative DR is up to 34.6% and 12.0%, respectively, whereas 25% of cases of vision loss associated with DR are caused by complications of proliferative DR. Colour fundus photography and optical coherence tomography are the most informative clinical diagnostic methods for DR. In severe stages of proliferative DR, the information content of the presented indicators can be significantly reduced because of insufficient visualisation of the patient’s fundus. Thus, the literature proposes qualitative criteria (specific and single indicators) based on an expert assessment of the condition of the fundus by an ophthalmic surgeon. The described approach has a fairly high diagnostic efficiency. Along with this, it appears relevant to study the ‘quality of life’ of a patient with symptoms of proliferative DR caused by the occurrence of characteristic manifestations of psychological distress (psychological and anxiety disorders and depression). In surgical terms, functional results notably improved after vitrectomy for proliferative DR in 49–83% of cases. Moreover, the proposed methods for conducting vitrectomy for patients with advanced stages of proliferative DR do not fully consider ophthalmological and somatic features, which requires the consideration of the surgical treatment of this contingent as a separate area of vitrectomy for improving ophthalmological ‘techniques’, drug support and choice of anaesthesia.

About the authors

Adam F. Teshev

Adygea Republican Clinical Hospital

Email: adam.teshev@gmail.com
ORCID iD: 0009-0002-2434-7538
SPIN-code: 1548-8310
Russian Federation, Maikop

Alexey V. Malyshev

Research Institute of Regional Clinical Hospital N 1 named after professor S.V. Ochapovsky

Email: mavr189@yandex.ru
ORCID iD: 0000-0002-1448-9690
SPIN-code: 1381-6881

MD, Dr. Sci. (Medicine), associate professor

Russian Federation, Krasnodar

Aleksandr S. Golovin

Leningrad Regional Clinical Hospital

Author for correspondence.
Email: asgolovin1982@gmail.com
ORCID iD: 0000-0002-4803-9241
SPIN-code: 7636-2314
Russian Federation, Saint Petersburg

References

  1. Neroev VV, Zaytseva OV, Mikhailova LA. Diabetic retinopathy prevalence in the Russian Federation according to all-Russia statistics. Russian Ophthalmological Journal. 2023;16(3):7–11. EDN: ZBWKBI doi: 10.21516/2072-0076-2023-16-3-7-11
  2. Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–1591. doi: 10.1016/j.ophtha.2021.04.027
  3. Thomas R, Halim S, Gurudas S, et al. IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract. 2019;157:107840. doi: 10.1016/j.diabres.2019.107840
  4. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024
  5. Zhang Y, Yang R, Hou Y, et al. Association of cardiovascular health with diabetic complications, all-cause mortality, and life expectancy among people with type 2 diabetes. Diabetol Metab Syndr. 2022;14(1):158. doi: 10.1186/s13098-022-00934-6
  6. Stewart MW, Browning DJ, Landers MB. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018;66(12):1751–1762. doi: 10.4103/ijo.IJO_1217_18
  7. Кaźmierczak K, Żuchowski P, Stafiej J, Malukiewicz G. Functional and structural outcomes and complications after pars planavitrectomy for severe features of proliferative diabetic retinopathy in type 1 and type 2 diabetes mellitus. PLoS One. 2023;18(7):e0288805. doi: 10.1371/journal.pone.0288805
  8. Scott RA, Lu VI, Grove N, et al. Rates of diabetic retinopathy among cluster analysis-identified type 2 diabetic mellitus subgroups. Graefes Arch Clin Exp Ophthalmol. 2023. doi: 10.1007/s00417-023-06260-5
  9. Rai BB, Essex RW, Morley MG, et al. Prevalence and severity of diabetic retinopathy at first presentation to vitreoretinal services in Bhutan: a 3-year national study. Jpn J Ophthalmol. 2023;67(3): 287–294. doi: 10.1007/s10384-023-00989-6
  10. GverovićAntunica A, Bućan K, Kaštelan S, et al. Prevalence of diabetic retinopathy in the Dubrovnik-Neretva County. Cent Eur J Public Health. 2019;27(2):160–164. doi: 10.21101/cejph.a5213
  11. Budzinskaia MV, Petrachkov DV, Savochkina OA, Arzhukhanov DD. On classification of diabetic retinopathy. The Russian Annals of Ophthalmology. 2019;135(5-2):272–277. EDN: GUPFSC doi: 10.17116/oftalma2019135052272
  12. Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of diabetic retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8): 747–754. doi: 10.1001/jamaophthalmol.2023.2289
  13. Stattin M, Haas AM, Ahmed D, et al. Detection rate of diabetic macular microaneurysms comparing dye-based angiography and optical coherence tomography angiography. Sci Rep. 2020; 10(1):16274. doi: 10.1038/s41598-020-73516-z
  14. Durzhinskaya MKh. Microaneurysms as a marker of diabetic retinopathy. The Russian Annals of Ophthalmology. 2021;137(5-2): 300–305 EDN: IZCQCA doi: 10.17116/oftalma2021137052300
  15. Parravano M, De Geronimo D, Scarinci F, et al. Diabetic microaneurysms internal reflectivity on spectral-domain optical coherence tomography and optical coherence tomography angiography detection. Am J Ophthalmol. 2017;179:90–96. doi: 10.1016/j.ajo.2017.04.021
  16. Querques G, Borrelli E, Battista M, et al. Optical coherence tomography angiography in diabetes: focus on microaneurysms. Eye (Lond). 2021;35(1):142–148. doi: 10.1038/s41433-020-01173-7
  17. Esmaeilkhanian H, Liu H, Fasih-Ahmed S, et al. The relationship of diabetic retinopathy severity scales with frequency and surface area of diabetic retinopathy lesions. Graefes Arch Clin Exp Ophthalmol. 2023;261(11):3165–3176. doi: 10.1007/s00417-023-06145-7
  18. Sears CM, Nittala MG, Jayadev C, et al. Comparison of subjective assessment and precise quantitative assessment of lesion distribution in diabetic retinopathy. JAMA Ophthalmol. 2018;136(4):365–371. doi: 10.1001/jamaophthalmol.2018.0070
  19. Santos AR, Mendes L, Madeira MH, et al. Microaneurysm turnover in mild non-proliferative diabetic retinopathy is associated with progression and development of vision-threatening complications: a 5-year longitudinal study. J Clin Med. 2021;10(10):2142. doi: 10.3390/jcm10102142
  20. Marques IP, Alves D, Santos T, et al. Characterization of disease progression in the initial stages of retinopathy in type 2 diabetes: a 2-year longitudinal study. Invest Ophthalmol Vis Sci. 2020;61(3):20. doi: 10.1167/iovs.61.3.20
  21. Nagasawa T, Tabuchi H, Masumoto H, et al. Accuracy of diabetic retinopathy staging with a deep convolutional neural network using ultra-wide-field fundus ophthalmoscopy and optical coherence tomography angiography. J Ophthalmol. 2021;3(4):2021:6651175. doi: 10.1155/2021/6651175
  22. Russell JF, Flynn HW Jr, Sridhar J, et al. Distribution of diabetic neovascularization on ultra-widefield fluorescein angiography and on simulated widefield OCT angiography. Am J Ophthalmol. 2019;207:110–120. doi: 10.1016/j.ajo.2019.05.031
  23. Schwartz R, Khalid H, Sivaprasad S, et al. Objective evaluation of proliferative diabetic retinopathy using OCT. Ophthalmol Retina. 2020;4(2):164–174. doi: 10.1016/j.oret.2019.09.004
  24. Shoshani Y, Harris A, Shoja MM, et al. Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes. Clin Exp Ophthalmol. 2012;40(7):697–705. doi: 10.1111/j.1442-9071.2012.02778.x
  25. Vaz-Pereira S, Morais-Sarmento T, Esteves Marques R. Optical coherence tomography features of neovascularization in proliferative diabetic retinopathy: a systematic review. Int J Retina Vitreous. 2020;6:26. doi: 10.1186/s40942-020-00230-3
  26. Golovin AS, Belikova EI. A comparative qualitative assessment of the severity of diabetic retinopathy in patients with stages III, IV and V, requiring hemodialysis, of chronic renal insufficiency. Russian Ophthalmological Journal. 2022;15(4):18–22. EDN: KINIVC doi: 10.21516/2072-0076-2022-15-4-18-22
  27. Roberts-Martínez Aguirre I, Rodríguez-Fernández P, González-Santos J, et al. Exploring the quality of life related to health and vision in a group of patients with diabetic retinopathy. Healthcare (Basel). 2022;10(1):142. doi: 10.3390/healthcare10010142
  28. Ströhle A, Gensichen J, Domschke K. The diagnosis and treatment of anxiety disorders. Dtsch Arztebl Int. 2018;155(37): 611–620. doi: 10.3238/arztebl.2018.0611
  29. Valluru G, Costa A, Klawe J, et al. Depression in individuals with diabetic retinopathy in the US national health and nutrition examination survey, 2005–2008. Am J Ophthalmol. 2023;256:63–69. doi: 10.1016/j.ajo.2023.07.005
  30. Terheyden JH, Finger RP. Vision-related quality of life with low vision — assessment and instruments. Klin Monbl Augenheilkd. 2019;236(3):261–268. (In Germany). doi: 10.1055/a-0838-5810
  31. Assi L, Rosman L, Chamseddine F, et al. Eye health and quality of life: an umbrella review protocol. BMJ Open. 2020;10(8):e037648. doi: 10.1136/bmjopen-2020-037648
  32. Ovechkin IG, Kovrigina EI, Konovalov ME, Kumar V. Quality of life study in ophthalmic practice. Ophthalmology Reports. 2021;14(3): 61–70. EDN: RFIOGN doi: 10.17816/OV71041
  33. Perais J, Agarwal R, Evans JR, et al. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. Cochrane Database Syst Rev. 2023;2(2):CD013775. doi: 10.1002/14651858.CD013775.pub2
  34. Zhang Y, Zhu W, Wang J, Zuo Y. Identification of biomarkers associated with immune scores in diabetic retinopathy. Front Endocrinol (Lausanne). 2023;14:1228843. doi: 10.3389/fendo.2023.1228843
  35. Zhou JB, Song ZH, Bai L, et al. Retraction note: could intensive blood pressure control really reduce diabetic retinopathy outcomes? Evidence from meta-analysis and trial sequential analysis from randomized controlled trials. Diabetes Ther. 2023;14(5):951. doi: 10.1007/s13300-023-01396-3
  36. Kataoka SY, Lois N, Kawano S, et al. Fenofibrate for diabetic retinopathy. Cochrane Database Syst Rev. 2023;6(6):CD013318. doi: 10.1002/14651858.CD013318.pub2.
  37. Lee CC, Hsing SC, Lin YT, et al. The importance of close follow-up in patients with early-grade diabetic retinopathy: a taiwan population-based study grading via deep learning model. Int J Environ Res Public Health. 2021;18(18):9768. doi: 10.3390/ijerph18189768
  38. Gange WS, Lopez J, Xu BY, et al. Incidence of proliferative diabetic retinopathy and other neovascular sequelae at 5 years following diagnosis of type 2 diabetes. Diabetes Care. 2021;44(11):2518–2526. doi: 10.2337/dc21-0228
  39. Hsieh YT, Hsieh MC. Time-sequential correlations between diabetic kidney disease and diabetic retinopathy in type 2 diabetes — an 8-year prospective cohort study. Acta Ophthalmol. 2021;99(1): e1–e6. doi: 10.1111/aos.14487
  40. Storey PP, Ter-Zakarian A, Philander SA, et al. Visual and anatomical outcomes after diabetic traction and traction-rhegmatogenous retinal detachment repair. Retina. 2018;38(10): 1913–1919. doi: 10.1097/IAE.0000000000001793
  41. Huang CH, Hsieh YT, Yang CM. Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):863–871. doi: 10.1007/s00417-016-3579-4
  42. Nishi K, Nishitsuka K, Yamamoto T, Yamashita H. Factors correlated with visual outcomes at two and four years after vitreous surgery for proliferative diabetic retinopathy. PLoS One. 2021;16(1):e0244281. doi: 10.1371/journal.pone.0244281
  43. Cruz-Iñigo YJ, Berrocal MH. Twenty-seven-gauge vitrectomy for combined tractional and rhegmatogenous retinal detachment involving the macula associated with proliferative diabetic retinopathy. Int J Retina Vitreous. 2017;3:38. doi: 10.1186/s40942-017-0091-x
  44. Im JC, Kim JH, Park DH, Shin JP. Structural changes of the macula on optical coherence tomography after vitrectomy for proliferative diabetic retinopathy. Ophthalmologica. 2017;238(4): 186–195. doi: 10.1159/000477826
  45. Algethami A, Talea M, Alsakran WA, et al. Persistent subretinal fluid following diabetic tractional retinal detachment repair: risk factors, natural history, and management outcomes. Int Ophthalmol. 2021;41(2):453–464. doi: 10.1007/s10792-020-01595-y
  46. Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. doi: 10.1136/bmj.m997
  47. DCCT/EDIC Research Group, Nathan DM, Bebu I, et al. Frequency of evidence-based screening for retinopathy in type 1 diabetes. N Engl J Med. 2017;376(16):1507–1516. doi: 10.1056/NEJMoa1612836
  48. Golovin AS, Belikova EI. Scientific substantiation, development, evaluation of the safety and clinical efficacy of vitrectomy technology in patients with severe forms of proliferative diabetic retinopathy who are on hemodialysis. Ophthalmology. 2022;19(4):746–752. EDN: ONYTOU doi: 10.18008/1816-5095-2022-4-746-752
  49. Bikbov MM, Fayzrakhmanov RR, Kalanov MR. Effect of internal limiting membrane peeling on morpho-functional state of the retina in patients with proliferative diabetic retinopathy (preliminary report). The Russian Annals of Ophthalmology. 2018;134(1):63–69. EDN: YSGVWV doi: 10.17116/oftalma2018134163-69
  50. Konovalova KI, Shishkin MM, Fayzrakhmanov RR. Effectiveness of multistage surgical treatment of advanced proliferative diabetic retinopathy complicated with primary cataract. The Russian Annals of Ophthalmology. 2020;136(6-2):171–176. EDN: NOWWJG doi: 10.17116/oftalma2020136062171
  51. Babayeva DB, Shishkin MM, Fayzrakhmanov RR, Konovalova KI. Vitreopapillary traction syndrome in patients with proliferative diabetic retinopathy. Vestn Oftalmol. 2021;137(6):38–44. EDN: AHZKOG doi: 10.17116/oftalma202113706138
  52. Li S, Yang Y, Zou J, et al. The efficacy and safety of intravitreal injection of Ranibizumabas pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage. BMC Ophthalmol. 2022;22(1):63. doi: 10.1186/s12886-022-02303-3
  53. Gale MJ, Scruggs BA, Flaxel CJ. Diabetic eye disease: a review of screening and management recommendations. Clin Exp Ophthalmol. 2021;49(2):128–145. doi: 10.1111/ceo.13894

Copyright (c) 2024 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies